Notice of NIBIB Specific Interests and Guidance in RFA-NS-23-006 HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)
Notice Number:
NOT-EB-22-012

Key Dates

Release Date:

January 9, 2023

Related Announcements

RFA-NS-23-006 - HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)

Issued by

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Purpose

The purpose of this Notice is to inform applicants that the National Institute of Biomedical Imaging and Bioengineering (NIBIB) will participate, effective immediately, in RFA-NS-23-006 "HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)".

The following changes and updates are made to RFA-NS-23-006 (shown in italics) to reflect NIBIB participation in this FOA.
 

Part 1. Overview Information
 

Components of Participating Organizations

National Institute of Neurological Disorders and Stroke (NINDS)

National Heart, Lung, and Blood Institute (NHLBI)

National Institute on Aging (NIA)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute of General Medical Sciences (NIGMS)

National Institute of Mental Health (NIMH)

National Center for Complementary and Integrative Health (NCCIH)

National Center for Advancing Translational Sciences (NCATS)

National Cancer Institute (NCI)

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.853, 93.273, 93.846, 93.350, 93.837, 93.838, 93.839, 93.840, 93.233, 93.865, 93.213, 93.859, 93.866, 93.351, 93.242, 93.395, 93.396 93.286

 

Section I. Funding Opportunity Description

B. NIH Institute and Center Interests and Guidance

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

The mission of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) is to improve human health by leading the development and accelerating the application of biomedical technologies. The Institute is committed to integrating engineering with the physical and life sciences to advance basic research and medical care. The Small Business Program at the NIBIB helps to achieve this mission by supporting innovative technologies to improve the prevention, detection, treatment, and monitoring of disease and disorders through various stages of commercial research and development.The NIBIB welcomes SBIR applications from small businesses proposing ideas relevant to its scientific program areas. NIBIB supports research from early-stage technology development through first in human demonstrations and early feasibility clinical studies.


All other aspects of this Notice remain the same.

Inquiries

Please direct all inquiries to:

Kari R Ashmont, PhD
National Insititute of Biomedical Imaging and Bioengineering (NIBIB)
Email: nibib-sbir@mail.nih.gov